ASMB on Nasdaq
ASSEMBLY BIOSCIENCES, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Bicycle Therapeutics (United Kingdom), Viridian Therapeutics, Inc.\DE or OMEROS CORP, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-16.8%Operating margin3
-8.5%Net margin3
153.5%Revenue growth, 20253
-3.0%Return on equity3
-$41.2MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development90¢$64.8M
- Other costs10¢$7.5M
Out of $72.3M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration revenue from a related party | $72.3M | $28.5M |
| Research and development | $64.8M | $55.9M |
| General and administrative | $19.6M | $18.0M |
| Total operating expenses | $84.4M | $73.9M |
| Loss from operations | -$12.1M | -$45.4M |
| Interest and other income, net | $6.0M | $5.6M |
| Total other income | $6.0M | $5.6M |
| Loss before income taxes | -$6.1M | -$39.8M |
| Income tax expense | $0 | $330.0K |
| Net loss | -$6.1M | -$40.2M |
| Unrealized gain (loss) on marketable securities | $170.0K | -$130.0K |
| Comprehensive loss | -$6.0M | -$40.3M |
| Net loss per share - basic | -$0.55 | -$6.69 |
| Net loss per share - diluted | -$0.55 | -$6.69 |
| Weighted average common shares outstanding, basic | 11.2M shares | 6.0M shares |
| Weighted average common shares outstanding, diluted | 11.2M shares | 6.0M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $58.5M | $38.3M | |
| Marketable securities | $189.7M | $73.7M | |
| Accounts receivable from collaboration with a related party | $974.0K | $0 | |
| Prepaid expenses and other current assets | $5.5M | $3.4M | |
| Total current assets | $254.5M | $115.5M | |
| Property and equipment, net | $221.0K | $284.0K | |
| Operating lease right-of-use (ROU) assets | $2.5M | $3.1M | |
| Other assets | $312.0K | $312.0K | |
| Total assets | $257.6M | $119.2M | |
| Accounts payable | $1.2M | $585.0K | |
| Accrued research and development expenses | $2.4M | $2.3M | |
| Other accrued expenses | $7.7M | $6.9M | |
| Deferred revenue from a related party - short-term | $36.9M | $37.6M | |
| Operating lease liabilities - short-term | $569.0K | $461.0K | |
| Total current liabilities | $48.8M | $47.8M | |
| Deferred revenue from a related party - long-term | $0 | $35.4M | |
| Operating lease liabilities - long-term | $2.1M | $2.6M | |
| Total liabilities | $50.8M | $85.8M | |
| Common stock, $0.001 par value; 150,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 15,855,329 and 7,457,240 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $16.0K | $7.0K | |
| Additional paid-in capital | $1.0B | $859.5M | |
| Accumulated other comprehensive loss | -$41.0K | -$211.0K | |
| Accumulated deficit | -$832.0M | -$825.9M | |
| Total stockholders' equity | $206.8M | $33.4M | $41.1M |
| Total liabilities and stockholders' equity | $257.6M | $119.2M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 150.0M shares | 150.0M shares | |
| Common stock, shares issued | 15.9M shares | 7.5M shares | |
| Common stock, shares outstanding | 15.9M shares | 7.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$6.1M | -$40.2M |
| Depreciation and amortization | $129.0K | $129.0K |
| Stock-based compensation | $4.7M | $3.1M |
| Net accretion of investments in marketable debt securities | -$2.3M | -$3.7M |
| Non-cash rent expense | $851.0K | $1.4M |
| Realized gain on investments in marketable debt securities | -$3.0K | $0 |
| Accounts receivable from collaboration | -$974.0K | $43.0K |
| Prepaid expenses and other current assets | -$2.0M | $73.0K |
| Accounts payable | $586.0K | $124.0K |
| Accrued research and development expenses | $114.0K | $1.4M |
| Other accrued expenses | $887.0K | $1.1M |
| Deferred revenue from a related party | -$36.1M | -$13.3M |
| Operating lease liabilities | -$751.0K | -$1.4M |
| Net cash used in operating activities | -$41.1M | -$51.1M |
| Proceeds from maturities of marketable securities | $116.4M | $130.7M |
| Purchases of marketable securities | -$229.8M | -$90.5M |
| Purchases of property and equipment | -$66.0K | -$28.0K |
| Net cash (used in) provided by investing activities | -$113.5M | $40.2M |
| Proceeds from the issuance of common stock, pre-funded warrants and warrants in an underwritten offering, net of issuance costs | $123.6M | $0 |
| Proceeds from the issuance of common stock and warrants in private placements to a related party, net of issuance costs | $42.8M | $17.6M |
| Proceeds from the exercise of warrants | $5.5M | $0 |
| Proceeds from the issuance of common stock under ATM equity offering program, net of issuance costs | $1.9M | $2.0M |
| Proceeds from the issuance of common stock under ESPP | $725.0K | $150.0K |
| Proceeds from the exercise of stock options | $125.0K | $5.0K |
| Proceeds from the issuance of common stock and warrants in a registered direct offering, net of issuance costs | $0 | $9.7M |
| Net cash provided by financing activities | $174.7M | $29.4M |
| Net increase in cash and cash equivalents | $20.1M | $18.5M |
| Operating lease liabilities arising from obtaining ROU assets | $0 | $2.0M |
Former names
- VENTRUS BIOSCIENCES INCFeb 7, 2008 to Jul 11, 20142
Recent filings
- Aug 20, 2026S-8
- Aug 14, 20268-K/A
- Aug 14, 2026SCHEDULE 13G/A
- Aug 13, 2026SCHEDULE 13G/A
- Aug 13, 20268-K
- Aug 13, 202610-Q
- Aug 4, 2026SCHEDULE 13G/A
- Jun 18, 20264
- Jun 5, 20268-K
- Jun 5, 20264
- Jun 5, 20264
- Jun 5, 20264
- Jun 5, 20264
- Jun 5, 20264
- Jun 5, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10